companies / quincetx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-14 json
| total_raised | 114,720,542114.7M | ○ |
|---|---|---|
| founded | null | |
| hq | South San Francisco, CA | |
| industry | unknown | |
| stage | null |
Quince Therapeutics is a late-stage biotech treating rare diseases via its AIDE platform, which encapsulates drugs inside a patient's own red blood cells. Its lead program targets Ataxia-Telangiectasia, a rare genetic disorder. Its edge is using autologous red blood cells to improve tolerability and half-life while cutting immunogenicity.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-06-11 | Funding round | 114,720,542114.7M | null | ○ |
adobe fonts, apache, apache http server, imagesloaded 4.1.4, jquery 3.7.1, jquery migrate 3.4.1, mysql, parallax.js, php, typekit, wordpress 6.5.8, wordpress block editor
| fact | status | src |
|---|---|---|
| Funding round, $114.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $114.7M, 2026-06-11 → Funding round, $114.7M, 2026-06-11, ○ 2026-06-14 | latest_round | seed, $114.7M, 2026-06-11 → Funding round, $114.7M, 2026-06-11 | ○ 2026-06-14 |
Records begin 2026-09-24. all_changes